Dr. Jill Smith, MD

• Gastroenterology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Mo

  Fellowship Hospital, 1987

• University Of Florida College Of Medicine

  Medical School, 1980

• Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma, 2023-02-11

• Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment, 2021-09-30

• Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model, 2021-08-24

• Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic, 2023-05-18

• DISTRIBUTION OF CCK-B RECEPTOR GENOTYPE BETWEEN PANCREATIC CANCER PATIENTS AND CONTROLS AND ITS IMPACT ON SURVIVAL, 2014-10-24

• Target-Specific Nanoparticle Polyplex Down-Regulates MutantKrasto Prevent Pancreatic Carcinogenesis and Halt Tumor Progression, 2023-01-01

• Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer, 2021-12-01

• Characterizingcis-regulatory variation in the transcriptome of histologically normal and tumor-derived pancreatic tissues, 2017-06-20

• Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis, 2019-10-09

• Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment, 2022-03-12

• A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma, 2017-02-01

• ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression, 2019-11-11

• 4121 The beneficial, anti-fibrotic effects of chemokine receptor 2 and 5 antagonists on fat-exposed mouse primary hepatic stellate cells (pHSCs), 2020-06-01

• A Cholecystokinin Receptor Antagonist Halts Non-alcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma, 2019-07-11

• Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer, 2020-10-28

• Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment, 2019-09-24

• Cholecystokinin Mediates Progression and Metastasis of Pancreatic Cancer Associated with Dietary Fat, 2014-05-11

• Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer, 2018-02-08

• Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice, 2017-10-17

• Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome, 2022-02-08

• Effective Encapsulation and Biological Activity of Phosphorylated Chemotherapeutics in Calcium Phosphosilicate Nanoparticles for the Treatment of Pancreatic Cancer, 2017-07-01

• 25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma, 2021-03-30

• Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas, 2021-11-25